Physician profile
Keith Ladendorf
NPI 1619092095
$2,867.56
in general payments reported to CMS, 2019-2025
17 companies · $475 in 2025
The $475 reported for 2025 was more than what 79% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,033 · 2023: $721 · 2024: $639 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,834.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $923.62 | 2021 | |
| Getinge USA Sales, LLC | $415.46 | 2021-2025 | Vasoview Hemopro 2, Vasoview Hemopro 2 |
| Atricure, INC. | $349.23 | 2021-2023 | |
| Edwards Lifesciences Corporation | $328.39 | 2023-2024 | Sapien 3 Ultra Resilia |
| Chiesi USA, INC. | $162.39 | 2023-2025 | Cleviprex, Curosurf |
| Genzyme Corporation | $149.61 | 2025 | |
| Ethicon US, LLC | $122.80 | 2021-2025 | Prolene, Vistaseal |
| Terumo Cardiovascular Systems Corporation | $114.06 | 2025 | Herc Flex Universal Stabilizer Arm, Virtuosaph Plus With Radial Indication |
| Lightbody Medical Technologies INC | $79.62 | 2024-2025 | |
| La Jolla Pharmaceutical Company | $53.04 | 2023-2024 | Giapreza |
| Merck Sharp & Dohme LLC | $46.51 | 2025 | Keytruda |
| Davol INC. | $27.54 | 2025 | Arista |
| Haemonetics Corporation | $23.07 | 2024 | Teg6s Hemostasis System |
| Medtronic, INC. | $20.28 | 2021 | |
| Lemaitre Vascular, INC. | $19.79 | 2024 | Tyke, Patch, Pledget and Intracardiac |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $19.30 | 2024 | Pico, Renasys Go V2 Home |
| Janssen Pharmaceuticals, INC | $12.85 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Ladendorf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.